FDA-approved antibiotic improves motor function in a rat hemi-parkinsonian model: Potential to extend timeline in early-stage Parkinson's disease
| dc.contributor.author | Salvatore, Michael | |
| dc.contributor.author | McElroy, Christopher | |
| dc.contributor.author | Shifflet, Marla | |
| dc.creator | Kasanga, Ella | |
| dc.date.accessioned | 2020-12-12T18:29:24Z | |
| dc.date.available | 2020-12-12T18:29:24Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Purpose: The motor deficits of Parkinson's disease (PD): bradykinesia, resting tremors, postural instability and/or rigidity are predominantly unilateral early at diagnosis, progressing bilaterally into moderate stages of the disease. In rats, unilateral impairment can be generated using the neurotoxin 6-hydroxydopamine (6-OHDA). Progression of these deficits can be evaluated to provide insight into gradual bilateral impairment and resulting neuropathological changes. This study employed two locomotor function assays: the forepaw adjusting steps (FAS), which is an 'imposed-movement' test and the open-field locomotor (OFL) test, which relies on "at-will' movement, to longitudinally evaluate bradykinesia and impact of an FDA-approved antibiotic, initiated after lesion induction, as a potential repurposed drug in a 6-OHDA model. Method: 3-month old male Sprague-Dawley rats were evaluated at four time-points after lesion induction (days 7, 14, 21 and 28). Results: The OFL tests did not reveal any significant change in activity although there was a trend towards a decrease in ambulatory counts in the lesioned group over the 4-week period. However, FAS revealed a sustained deficit in right forepaw use (~50 %) while a compensatory increase in the use of the unaffected (left) forepaw was observed. The antibiotic further increased left forepaw use although no significant improvement was seen with the OFL test. Conclusion: Lesioning of the nigrostriatal pathway led to a transient compensatory increase in left forepaw use, an effect which was sustained by antibiotic administration suggesting a benefit that may curtail the onset of bilateral impairment. | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12503/30250 | |
| dc.language.iso | en | |
| dc.title | FDA-approved antibiotic improves motor function in a rat hemi-parkinsonian model: Potential to extend timeline in early-stage Parkinson's disease | |
| dc.type | poster | |
| dc.type.material | text |